Navigation Links
Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease
Date:6/15/2011

, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that Generx can be successfully advanced in clinical studies outside of the U.S.; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the ASPIRE clinical study will be successful or will lead to approval of Generx by the Russian Health Authority for marketing and sales in Russia or lead to approvals in other countries of the Commonwealth of Independent States; that additional clinical evidence regarding the safety and effectiveness of Generx that might be obtained in Russia would be useful for optimizing and broadening commercial development pathways in other industrialized countries; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the regulatory or commercialization activities of Generx in the U.S. or other markets; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual re
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
4. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
5. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
6. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
7. Multiple Presentations Confirm Clinical Efficacy and High Rate of Patient Compliance Using Provent® Sleep Apnea Therapy to Treat Obstructive Sleep Apnea
8. Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available Soon From OCuSOFT®
9. Accuray Successfully Completes Acquisition of TomoTherapy
10. Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
11. TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
(Date:7/31/2015)... 31, 2015  Boston Children,s Hospital physicians report ... printing of their anatomy before undergoing high-risk brain ... (abnormalities in the brain,s blood vessels) that posed ... in the Journal of Neurosurgery: Pediatrics , ... and synthetic resins to create custom, high-fidelity models ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... A number of costs associated with nonprescription drug ... and a half years. Certain material costs for plastic ... during this time, increasing packaging expenses. Advertising and marketing ... the majority of marketers reduced advertising costs in 2009, ...
... ERT (Nasdaq: ERES ) announced today ... 2010 on Thursday, November 4, 2010, after the market closes. ... at 5:00 PM EDT that day. For ... within the United States or 1-412-858-4600 when calling internationally. There ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/3/2015)... Hollywood, FL (PRWEB) , ... ... ... internet’s most-visited bodybuilding and fitness site and the largest online retailer of ... Supplement Awards. BPI Sports is up for 11 awards in the following ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing ... the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le ... of the Company’s presentation may be accessed via the investor relations section of the ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug ... Kybella is similar to deoxycholic acid, which occurs naturally in the body and helps ... to treat this area of the body. These are invasive procedures and very expensive ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... predicted to decline by 39 percent, according to market research compiled for the ... data from the U.S. Department of Labor, Bureau of Labor Statistics. As the ...
Breaking Medicine News(10 mins):Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... Dec. 17 HealthSouth,Corporation (NYSE: HLS ) today ... EST on Tuesday, Feb. 24, 2009, to discuss its results ... The conference call may ... 76626362. International callers should dial (973) 582-2847 and,give the same ...
... ATLANTA, Dec. 17, 2008, The AMERIGROUP Foundation announced ... Outreach worker at West End Medical Centers, by designating ... Ms. Roper has contributed significantly to the ... years of extensive neighborhood involvement. For the past ...
... those with pulmonary clots saw benefit, , , WEDNESDAY, Dec. ... the clot-dissolving drug tenecteplase (TKNase) to people with sudden ... a form of tissue plasminogen activator (tPA), didn,t work ... up on the idea. , "In specific situations, those ...
... 17 Human Pheromone,Sciences, Inc. (OTC Bulletin Board: EROX) ... Comprehensive Patent Application with the U.S. Patent and,Trademark Office ... with its origin in sea coral, which has significant ... positive social relationships,personal well-being and social attraction. , ...
... request of the presidential transition team, ideas on advancing ... today by the American College of Physicians (ACP). ... student members. It is the nation,s largest medical ... membership organization. , "ACP believes that it is essential ...
... leader in the planning and development of sustainable, social and ... Dr. Theresa Ramsey,s Center For Natural Healing to create OTP2 ... the focus of the collaboration - to provide consulting services ... , , OTP2 brings together ...
Cached Medicine News:Health News:HealthSouth Announces Date of 2008 Fourth Quarter and Year-End Earnings Conference Call 2Health News:Fredericka Roper of Atlanta Honored as 'Healthy Hero' By the AMERIGROUP Foundation 2Health News:Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients 2Health News:Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients 3Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Internists ask President-elect Obama to include aid for primary care in stimulus proposal 2Health News:Internists ask President-elect Obama to include aid for primary care in stimulus proposal 3Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 2Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 3Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 4
... might just be the world's most versatile ... support, post-op/rehab support, or both, Flex is ... Accutrac™ ROM hinges control flexion and extension ... durability while being heat-moldable to accommodate changes ...
... The Drytex Adjustable Patella Donut is ... unique nylon core and polyester Lycra ... A trimable full-circumference donut provides for ... have neoprene based allergies or irritations. ...
... The cool version of the TROM ... range-of-motion and locking capabilities as the full ... warmer climates. The ease of use and ... a variety of protocols following major ligament ...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Medicine Products: